Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial
ICEMAN (Intelligent Choice of Excision Margin): A Randomized Controlled Trial of Narrow Excision Versus Wide Excision for Adults With Primary Invasive Cutaneous Melanomas
Sponsor: OHSU Knight Cancer Institute
This NA trial investigates Clinical Stage IA Cutaneous Melanoma AJCC v8 and Clinical Stage IB Cutaneous Melanoma AJCC v8 and is currently actively recruiting participants. OHSU Knight Cancer Institute leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
4 versions recorded-
Mar 2026 — Present [monthly]
Recruiting NA
-
Jun 2025 — Mar 2026 [monthly]
Recruiting NA
-
Jan 2025 — Jun 2025 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- OHSU Knight Cancer Institute
- Oregon Health and Science University
For direct contact, visit the study record on ClinicalTrials.gov .